Cyanotic Congenital Heart Disease
9
1
1
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.1%
1 terminated out of 9 trials
85.7%
-0.8% vs benchmark
11%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Prenatal Maternal Mental Health and Neurodevelopment in Congenital Heart Disease
Predicting Factors for Mortality in Congenital Heart Disease Patients After Shunt Procedure in Developing Country.
Propofol vs Sevoflurane in Cyanotic Congenital Heart Disease
Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial
Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease
Cardiac Biomarkers in Patients With Single Ventricle Physiology
Preventing Brain Injury in Infants With Congenital Heart Disease
Accuracy of Pulse Oximeter With Hypoxemic Measurements
Probiotics in Infants With Cyanotic Congenital Heart Disease